Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $82.3 million.

  • Beam Therapeutics' Shares Outstanding (Diluted Average) rose 24.46% to $102.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 24.46%. This contributed to the annual value of $82.3 million for FY2024, which is 6.69% up from last year.
  • Beam Therapeutics' Shares Outstanding (Diluted Average) amounted to $82.3 million in FY2024, which was up 6.69% from $77.2 million recorded in FY2023.
  • Beam Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $82.3 million during FY2024, with a 5-year trough of $46.7 million in FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $76.5 million, with a median of $77.2 million in 2023.
  • Data for Beam Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 621.24% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Beam Therapeutics' Shares Outstanding (Diluted Average) stood at $46.7 million in 2020, then soared by 37.43% to $64.2 million in 2021, then grew by 9.01% to $70.0 million in 2022, then grew by 10.19% to $77.2 million in 2023, then grew by 6.69% to $82.3 million in 2024.